Page 1

29 November 2021 truscreen NZX / ASX Announcement a world without cervical cancer TruScreen unaudited interim results for the half - year ended 30 September 2021 Highlights for Half Year ended 30 September 2021 Strong revenue and Single Use Sensor sales growth of 25 % and 35 % year on year respectively Launch of TruScreen Made in China device for the Chinese market • Firmware upgrade and cervical cancer screening device enhancements • • Continuous expansion and first sales in Eastern Europe Ongoing excellent trial results confirm efficacy of TruScreen cervical cancer screening device TruScreen Group Limited ( NZX / ASX : TRU ) ( ' TruScreen ' or ' the Company ' ) is pleased to announce its unaudited half year financial results for the period ended 30 September 2021. TruScreen reports according to the New Zealand financial year , which runs from 1 April to 31 March . Strong revenue growth of 25 % The Company reported an operating loss of $ 1.26m ( 1H FY21 : $ 1.51m ) , a 20 % reduction over the prior year . Despite the negative impacts of COVID - 19 in some of our markets , notably Russia and Vietnam , product revenue increased by 25 % year on year ( YOY ) . Pleasingly , Single Use Sensor ( SUS ) unit sales were 35 % higher YOY , although getting new cervical cancer screening devices installed in hospitals was hampered by ongoing COVID - 19 restrictions . Net operating cash outflow was $ 1.7m ( 1H FY21 : $ 1.6m ) . An Australian research and development tax offset was received just after quarter - end in the amount of $ 0.6m . Cash operating costs were 22 % higher in 1H FY22 , at $ 2.5m ( 1H FY21 : $ 2.1m ) , reflecting the Company's increased investment in research and development which resulted in re - engineered firmware that enhanced cybersecurity and facilitated self - calibration which will reduce future operating costs . The Australian tax offset for the related research will be received in the next financial year . The loss for the six months included a non - cash amortisation and depreciation charge of $ 0.30m ( 1H FY21 : $ 0.35m ) . As at 30 September 2021 , the Company had cash and cash equivalents of $ 3.67m , which was supplemented by a research and development tax offset receipt of $ 0.6m from the Australian Tax Office on 1 October 2021 . Operational Update TruScreen continued to make good market and technical progress in 1H 22 and , going forward , is well placed to build upon this success as the COVID - 19 pandemic wanes throughout our markets .